title: Evaluation of a special combination of glucan with organic selenium derivative in different murine tumor models.
abstract: β-glucans are well-established immunomodulators with strong effects resulting in slowing or even inhibiting cancer growth. Recent studies have repeatedly suggested that the biological activities of β-glucan can be potentiated by the addition of other bioactive agents. In the current study, we focused on the anticancer effects of a combination of yeast-derived β-glucan and a selenium-linked pseudodisaccharide. Using three different models of murine cancer, we showed that this combination strongly suppressed the growth of all three types of cancers, most likely via the interaction with natural anticancer antibodies.
authors.affiliation: Department of Pathology, University of Louisville, Louisville, KY, U.S.A. vaclav.vetvicka@louisville.edu.
authors.forename: Vaclav
authors.initials: V
authors.lastname: Vetvicka
authors.affiliation: Department of Fundamental Chemistry/Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil.
authors.forename: Marcos Felipe
authors.initials: MF
authors.lastname: Pinatto-Botelho
authors.affiliation: Department of Fundamental Chemistry/Institute of Chemistry, University of São Paulo, São Paulo, SP, Brazil.
authors.forename: Alcindo A
authors.initials: AA
authors.lastname: Dos Santos
authors.affiliation: Department of Research and Development, Biorigin Company, Lençóis Paulista, SP, Brazil.
authors.forename: Carlos A F
authors.initials: CA
authors.lastname: De Oliveira
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018827:Carcinoma, Lewis Lung / Q000188:drug therapy*; D045744:Cell Line, Tumor; D003520:Cyclophosphamide / Q000627:therapeutic use; D004187:Disaccharides / Q000627:therapeutic use; D005260:Female; D005936:Glucans / Q000627:therapeutic use*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D051379:Mice; D008807:Mice, Inbred BALB C; D016566:Organoselenium Compounds / Q000627:therapeutic use*; D011509:Proteoglycans / Q000627:therapeutic use*; D018125:Receptors, Transforming Growth Factor beta / Q000627:therapeutic use*; D000077185:Resveratrol; D013267:Stilbenes / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D004187:Disaccharides; D005936:Glucans; D007155:Immunologic Factors; D016566:Organoselenium Compounds; D011509:Proteoglycans; D018125:Receptors, Transforming Growth Factor beta; D013267:Stilbenes; C071736:betaglycan; D003520:Cyclophosphamide; D000077185:Resveratrol
keywords: Glucan; breast cancer; cancer; immunity; lung cancer; organic selenium